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Abstract:
Fracture nonunions comprise one of the serious clinical complications in orthopedics. Fracture nonunions
result when the time to union is greater than 6 to 9 months. It is estimated that approximately 5% to 10%
of all fractures progress to fracture nonunion due to a host of complicating patient variables and risk
factors. New scoring systems have emerged which help in directing the treatment strategies. Fracture
nonunion management should be directed toward maintaining the diamond concept which introduces
osteogenic cells lines, an osteoconductive scaffold for those cells to grow, as well as the necessary growth
factors, and a stable mechanical microenvironment. This paper will focus on some of the promising
research that has been done in the field of orthopedics for the treatment of fracture nonunion, particularly
the use of mesenchymal stem cells, bone marrow aspirates, and biophysical manipulations such as the use
of electromagnetic fields, and their effects on cell cultures, animal models, and clinical studies.
One Sentence Summary:
This review explores some of the latest avenues of research which seek to improve the treatment process
for fracture nonunion by enhancing the rate of bone growth.
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Introduction
After a fracture, bone tissue has the remarkable ability to repair and remodel itself in an
expedient and well-orchestrated manner. This healing process relies on the coordination and
dissemination of many growth signals and inflammatory signals throughout the injured bone
tissue which work together to form a structurally sound bone to support the weight of the human
body. The molecular signaling events that occur during bone healing present a unique case study
in systems biology, and as such, there are many molecular targets which can be exploited to
speed up or resume the process. When this delicate signaling process becomes interrupted
through lack of stability, lack of healing time, or molecular inhibition at the level of growth
factors, it can result in a fracture nonunion or delayed union. One of the first studies which
examined the genetic basis for nonunion was done in 2011. This study sought to understand
whether there were differences in genes encoding growth factors. It was found that there were
single nucleotide polymorphisms (SNPs) in bone morphogenetic proteins (BMP-7, BMP-2); as
well as Smad6, and Noggin. Smad6 and Noggin are both inhibitors of the BMPs and in this study
it was found retrospectively that patients who developed nonunion had SNPs in these genes
which interfered with healing (12). Although the definition of a fracture nonunion in the clinical
setting can be arbitrary and much depends on the specific patient criteria, as noted by Zura et al.
such as age, prescribed drugs, tobacco use, mobility, and some genetic factors previously noted
(13).
formally, a nonunion can be defined as a complete halt or delay to the healing process in
bone tissue. The FDA defines fracture non-union as a fracture that is 9 months old which has not
made any significant healing progress within 3 months. A subset of this pathology is delayed
4

union which is defined as a lack of bony union within a 6 month window of time after the initial
injury, the distinguishing factor is that a delayed union shows some evidence of the healing
process, whereas a nonunion does not. Both pathologies are managed using similar procedures
(14).
Much of the diagnostic measures in fracture nonunions are dependent upon current
epidemiological estimates, which put the annual incidence of fracture nonunions in the United
States at 100,000 per year. This number represents only about 5% to 10% of all fractures that
occur (15). That may even be a low estimate of the incidence which depends entirely on the
diagnostic parameters used by physicians and the bones with which it occurs. Observational
Cohort studies reveal that the fracture nonunion risk
was varied with the bone in question and the severity
of the initial fracture. It is also reported that men are
more prone to nonunion than women.
When a nonunion develops, there are structural
classifications for the character of the fracture site.
One of the first incidences of an effort to classify the

Figure 1. This radiograph shows a hypertrophic nonunion
of the tibia with anteroposterior and lateral view. Of note is
the characteristic bony callus formation around the fracture
gap sometimes referred to as elephant’s foot (5).

structural elements of fracture nonunion site
was done by Weber and Chech in 1976 (16).
This classification is used to describe the
structure of the nonunion site through
radiographic appearance only. A
hypertrophic nonunion indicates that a callus

Figure 2. Atrophic nonunion of femoral shaft fracture following a vehicle
accident. Patient is a 38-year-old female. Initial treatment was performed
with intramedullary nail fixation technique with antirotational plating (DF). Union achieved after 5 months (F) (6).

has developed to stabilize the fracture site (figure 1), these calluses develop in the shape known
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as an elephant’s foot. this is typically due to a lack of initial stability from the point of injury
with sufficient vascularization present which contributes to the elephant’s foot formation.
Hypertrophic nonunions typically are a result of a mechanical failure from inadequate fixation or
premature patient mobility with adequate fixation (17). This excess mobility results in a lack of
healing despite all the necessary biological components and vascularization being present at the
site of tissue injury (18). Typically, hypertrophic nonunions maintain adequate vascularization
for healing and good clinical outcome is usually achieved with fixation using nail, plate, or
intramedullary approaches (19). An atrophic nonunion (figure 2) shows no callus development
which can indicate that there is likely a pathology at the cellular level which can be explained by
the risk factors and at the level of growth factors which is interferes with the mechanisms of
normal osteogenesis. Lack of blood supply to the fracture site along with strain forces are also
thought to be factors which can lead to atrophic nonunion(18). Oligotrophic nonunion shares
similar characteristics with both and is often considered an intermediate form. In the case of
these 3 types of nonunion, these distinguishing characteristics are based on appearance in
radiographs (20) (21). Fracture nonunions place a considerable burden on healthcare
infrastructure and the treatment costs increase substantially. The pain, prolonged hospital stays,
potential for infection, all result in a higher cost burden and risk to the patient. Due to the
substantial pain during recovery, this can increase the dependency on prescription opioids, which
was reported as high as 78% in some patient studies (22). Because of the complex nature of
fracture nonunions and the diverse variability that is present in a typical clinical presentation,
fracture nonunion of any category presents a unique challenge to orthopedic surgeons. The need
for novel inexpensive treatment options is necessitated by the diversity of this pathology and
burden placed on the patient and the healthcare system. This paper will explore the varying
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routes of research that exist to develop novel treatments and some of the future perspectives
within the field.
Emerging Classification Systems
As previously noted, there exists a large amount of variability in the way that each
fracture nonunion presents, as such, no two are alike, each patient must have a unique treatment
approach that is tailored to their medical history and fracture pathology. As with any disease
state, it is imperative to be able to measure and classify it so that a proper treatment regimen can
be directed against it. This concept of variability within orthopedic medicine makes research of
the fracture healing process in nonunions challenging to measure. Sources of variability within
orthopedic research exists in the following numerical and qualitative categories: age, sex,
developmental state, bone type, drug interactions,
fracture incidence, patient weight, and prior fractures
(15). To date, this has remained one of the greatest
challenges to overcome in proving which treatment is
the most effective for patients at varying severity
levels. Additionally, due to this variability there has
been a need to be able to algorithmically classify
the character of fracture nonunion so that the

Figure 3. The “diamond concept” of fracture healing
management proposed by Giannoudis et al. places
equal importance on the mechanics, osteogenic cells,
osteoconductive scaffold, and the growth factors
present at the fracture site.(8)

correct treatment approach can be tailored to the
patient based on their past medical history and current healing progress. Within the past decade,
this has ushered in a new scoring system to sort fracture nonunions based on a host of categories.
These categories fall under 4 themes: The growth factors present, cellular microenvironment,
bone matrix (scaffold), as well as the osteogenic cell lines present. These 4 categories together
7

form what is known as the “Diamond Concept”
shown in figure 3 (23) (8). Previous
classifications like the Weber and Chech
classification system relied solely on
radiographs for the determination of the
severity of nonunions. Calori et al proposed a
Figure 4. The ladder strategy devised by Calori et al shows the
implementation of the NUSS scoring system which indicates the
severity of a fracture nonunion. This system helps to direct the
treatment approach and eliminates the guess work. M is a major
mechanical issue, m is a minor mechanical problem, B is a major
biological issue and b is a minor biological issue. (4)

new Nonunion Scoring System (NUSS) (shown
in figure 4). New scoring systems like NUSS

take it a step further by incorporating a wholistic approach (combining risk factors with diamond
concept), as well as stability of the fracture, fracture gap, bone alignment, and soft tissue status.
In this scoring system, a number is assigned to a nonunion characteristic based on its severity,
higher severity traits receive a higher number and lower severity traits receive a lower score.
Patients who can be classified with a lower overall score typically require a less complex
intervention than those that receive a higher score which may require multiple different treatment
approaches based on how their score reflects the overall “Diamond Concept” of management
(23).
A retrospective clinical study by Calori et al sought to validate the NUSS. This study
included 300 patients over the age of 18 with nonunion of a long bone fracture. 198 patients were
male, 102 patients were female. Tibial shaft nonunion was found in 52% of patients, femoral
shaft nonunion in 17%, 11% in the humerus, 6% in the radius, 4% in the ulna. The patients were
divided into four total groups based on their NUSS scoring; patients in group 4 (shown in figure
4) (M+B) were not included in the study because their major defects prohibited the study of the
classification system. Clinical outcome was assessed both through radiographs and through
8

absence of severe pain and range of motion testing in comparison to contralateral unaffected
limb. This study demonstrated that statistically significant rates of union can be achieved if
fracture nonunions are classified in such a way that every patient characteristic and wound trait is
considered in order to direct the appropriate treatment course. The authors of this study
recommend that NUSS be implemented in every orthopedic center to maximize positive clinical
outcome for nonunion patients. The latest work that has been done in classification of fracture
nonunions is relevant to the overall discussion because classification of severity largely
determines which treatment modality best fits the patient (4).
Gold Standard for Treatment of Fracture Nonunion
In order to get a better picture of the frontiers of research in any treatment or therapeutic,
it is important to first understand the standard of treatment currently in use as a baseline
comparison. As such, the use of autologous bone grafts is the gold standard in orthopedic
medicine for the treatment of atrophic long bone fracture nonunions. This treatment most
commonly employs the use of host iliac crest cancellous bone as an osteogenic scaffold to
facilitate the process of osteogenesis. A careful examination of the patient outcome for
autologous bone grafting is warranted as well as the reasons for approaching the treatment of
nonunions from a different approach apart from the gold standard of care. Some would argue that
the search for alternative treatment options is largely driven by an industry reliant on producing
new forms of bioimplants and adjuvants. Conversely, as both general and orthopedic surgery
moves toward ever increasingly minimally invasive techniques, particularly in orthopedics, this
can be a benefit as it improves patient outcomes and postoperative pain. Additionally, the
limiting factor for autologous bone grafts is the quantity of cancellous bone that can be harvested
from the donor site. Iliac crest autograft comes with its own risks as well, there is a significant
9

level of donor site morbidity and complication rates (24) (25). Despite the increasing
development of alternatives to the autograft, many advantages persist. The primary advantage to
autologous bone grafting is that the tissue maintains histocompatibility since it is collected from
the patient’s own body. Secondly, the autologous graft is osteogenic, osteoinductive, and
osteoconductive. The most frequently used autologous graft is from cancellous bone found in the
iliac crest. Cancellous bone has trabecular bone structure which is a porous material lined with
osteoblasts attached to their porous scaffold which is made of mineral hydroxy appetite and
collagen fibers. Cortical bone grafts are less advantageous because there is less porous surface
area for osteoblasts to reside on and are often less osteoconductive (26).
A retrospective cohort study by Flierl et al. sought to understand which bone grafting
technique provided the best option for reducing the time to union in long bone fractures. Patient
inclusion criteria included patients with ages
ranging from 18 to 85 years old, admitted to
the hospital from January 1st, 1998 to
December 31st, 2010. This study found that
autologous or autograft was the most
effective treatment for reducing time to union
when compared to allograft and injection of
growth factors like rhBMP-2 (25).
Emerging Cell-Therapies, Mesenchymal Stem
Cells, and Growth Factors

Figure 5. Micro-CT scans that were done 14 days after
initial fracture reveal that fracture callus size, density,
volume increase with the presence of MSCs. Also
shown is the increase of hydroxy appetite HA (bone
mineral) content (mg) with the presence of MSCs. (2)

Mesenchymal stem cells are the
progenitors to mature osteoblasts and are
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crucial during the bone healing process. They are found in many tissues, of note, bone marrow.
Also crucial to the fracture healing process is the cytokine and growth factor environment
surrounding the fracture. The two bone morphogenetic proteins mentioned earlier, which are
members of the TGF-β superfamily, BMP-2 and BMP-7 are important in the process of bone
repair/growth and MSCs are defined as being cells which are plastic-adherent when cultured,
they express the following surface molecules: CD105, CD73, and CD90; they have multipotent
potential to differentiate into chondrocytes, adipocytes, and osteocytes.(27) By harnessing their
regenerative power in the case of a fracture
nonunion, the healing process can be sped up by
as much as half the time. placing them directly
into the wound site. MSCs can be induced to
differentiate into osteoblasts in vitro when
exposed to the necessary nutrient mediums and
growth factors that would be found in the wound
site of a fracture nonunion(27).
Transplanted MSCs have shown success
in animal models, particularly with rats. One
such study sought to understand the way in
which MSCs were able to migrate to the fracture

Figure 6. BLI showing the CXCR4 dependent migration of
MSCs to the fracture site in rats, BLI shown is done on a time
course of days 1, 3, 7, and 14. Initial localization is in the lung
fields of the rats, unsorted MSC are used as a control (MSC),
little to no migration is seen in rats with CXCR4(-) (2).

site and to determine their effect on the callus
formation during healing. It was shown through MSC expressing luciferase, that MSC migration
to the callus site is largely dependent on the chemokine receptor CXCR4, and that MSCs
improved the mechanical properties of the fracture site by enhancing the thickness of the
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cartilage and eventual bone callus around the fracture site (Figure 5). The authors found that
approximately 30% of the MSCs cultured from 4 mice were found to express CXCR4 using
immunoselection. The MSC cultures were grouped as MSC-CXCR4(+) and MSC-CXCR4(-).
Based on adenoviral vector Firefly luciferase under transcriptional control of a cytomegalovirus
promoter, bioluminescence imaging (BLI) was performed on a time course from 1 to 14 days
following a tibial fracture in the rats shown in figure 6. This data validates the migratory
behavior of MSCs toward the site of tissue injury. The authors also note findings of increased
fracture callus volume, density of hydroxy appetite, and total tissue volume which increases the
stability of the fracture site and aids in the healing process, as shown in figure 3. Further findings
of this study reveal that MSCs will lodge themselves into the endosteum that surrounds the
fracture callus. BMP-2 expression was found to be a prominent feature of the MSCs once they
migrated to the fracture site through BMP-2-Lac Z which is an essential growth factor for
controlling the fracture repair process, additionally no BMP expression was noted in specific
regions of the fracture callus which the authors hypothesize indicates an underlying regulatory
mechanism that would require further investigation. Taken together, these results indicate the
strong potential for MSCs to be utilized as a therapy for patients with difficult fracture
nonunions. This study provides foundational evidence for the use of cell-based therapies in
humans to modulate the molecular and inflammatory microenvironment to promote osteogenesis
(2).
The importance of BMPs in fracture healing and bone growth as a whole cannot be
overstated. BMPs are members of the TGF-β superfamily, they bind to two separate classes of
receptors which form heterodimers, ultimately leading to the phosphorylation of Smad proteins,
Smad then behaves as a transcription factor for proosteogenic target genes. Runx2 being of
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importance, which regulates the osteogenesis process (28). It has been shown in murine models
that deletion of the BMP genes leads to loss of proper skeletal development. When BMP2 and
BMP4 were both knocked out osteogenesis was halted completely (29). This data is consistent
with the findings of Dimitriou with regard to reduced function of BMP proteins through SNPs in
the human genome (12).
A promising type of cell-based therapy which harnesses the power of MSCs takes bone
marrow aspirate concentrate (BMAC) or isolated and expanded MSCs from bone marrow and
injects them directly into the fracture site. This utilizes the patient’s own bone marrow which is
centrifuged down to yield a concentrate (Buffy Coat) of stem cells which are then injected
directly into the fracture site. This technique is typically used in conjunction with an
osteoconductive scaffold for cells to adhere because although MSCs are osteogenic they require
a conducive environment to adhere and proliferate (osteoconductive scaffolds) (10).
A level III clinical study of note was carried out by
Hernigou et al, this study had 60 patients with aseptic atrophic
nonunion of the tibia. Bone marrow was aspirated from the iliac
crest and centrifuged down to a concentrate; each patient received
20 cc of concentrate which was injected directly into the fracture
site. This research team observed that there was a positive
correlation between the concentration in CFUs of fibroblasts and the

Figure 7. Comparison between
successful unions and failures of
union to the concentration in
cells/cm3 at the graft site (10).

total volume of the bone callus (10). Of the sixty patients, 7 of these patients did not achieve
bony union. The 6 patients who failed to achieve union had an average cell count of 634±187
progenitor cells/cm3 (p=0.001 significantly lower), than the 53 that achieved which union had an
average cell count of 2835±1160 progenitor cells/cm3 . One important aspect of this study is that
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it demonstrates that there is a positive correlation between the concentration of cells per cubic
centimeter at the fracture site and the rate of union. The authors note that there is no associated
negative inflammatory response which could interfere with healing. A limitation to this study is
that the MSCs were not isolated as they were in a mix of other progenitor cells in the aspirate,
including mononuclear cells, which
contributed to the milieu of cytokines.
additionally, there was no placebo control
group included (10).
Figure 8. Computed

A study done by Hernigou et al.
sought to examine the clinical outcome of

tomography images performed on a 45
year old patient prior to BMAC grafting and 6 months
after (right) show significant callus formation on the
femoral shaft around the fracture site (7).

injecting 20 cm3 of bone marrow aspirate which was concentrated and harvested from the

patient’s iliac crest. There were 60 patients who suffered from atrophic nonunion of the tibia.
Union was achieved in 53 out of 60 patients. In the fractures that failed to unite, the
concentration (p=0.001) and
number of cells (p<0.01) were
significantly less than the fractures
that did achieve union. The authors
note a positive correlation in their
findings between the amount of
bony callus formation and the
number and concentration of
fibroblast CFUs injected into the

Figure 9. Procedures performed by Sugaya et al injected the bone marrow
aspirate concentrate percutaneously directly into the fracture gap with the
bone marrow harvest needle over the course of 1 minute (7).

graft. Also noted in this study is that directly injecting the BMAC in vitro as opposed to
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expansion ex vitro minimized cellular aging, and reduced cell viability which are some of the
complicating factors with expansion of stem cells prior to injection (30).
Sugaya and colleagues performed a retrospective cohort study which analyzed patient
outcomes with atrophic fracture nonunion treated with autologous BMAC injections (Figure 9)
on 17 patients. This study is unique in that it also measured the pain in patients using visual
analog scale (VAS) on patients following BMAC grafting. Statistically significant reduction in
VAS was noted (P<0.001) in patients who achieved union with BMAC. Persistent and severe
fracture site pain is one of the symptoms of nonunion and the authors of this study believe that
achieving stability in the fracture site sooner was responsible for the alleviation of the pain. Of
the 17 patients who underwent treatment with BMAC 13 were observed to have radiographic
union after 12 months with no patients progressing to complications (7). The limitations to this
study were that the patient sample size was small, and it was retrospective. RCT trials need to be
conducted in multiple fracture nonunion sites to validate the results (7).
Along with injecting bone marrow aspirate concentrate directly into the fracture site,
studies have examined the patient outcomes when BMAC is combined with adjuvants such as
recombinant human bone morphogenic protein 2 (rhBMP-2) and demineralized bone matrix
(DBM) as an osteoconductive scaffold. One clinical study sought to demonstrate the use of
(rhBMP-2) combined with demineralized bone matrix (DBM) to treat fracture nonunions with a
fracture gap > 5 cm (31). Prior to this study, there was little evidence demonstrating that a
BMAC treatment course could be used to treat fracture gaps greater than 5 cm. The authors of
this study call the mixture of BMAC with DBM or rhBMP-2 the modified Hernigou technique.
In 49 patients with tibial fracture nonunion, they examined the radiologic healing time for
fracture gaps greater or less than 5 cm. They concluded that there was no significant difference
15

in the time to union (p=0.81) between patients with varying fracture gap size. 79.4% of the
patients in this study achieved radiographic union in an average 4.7 months. This study provides
a good basis for the application of BMAC with rhBMP-2 or DBM as an osteoinductive scaffold
(31).
Noninvasive Treatments (biophysical stimulation)
It has been known for more than a century that bone responds to physical stimuli with
growth. Julius Wolff, a German surgeon, first proposed in 1892 that bone will rearrange its
architecture to support the loads applied to it (32). Among other foundational works in the
understanding of bone was the discovery of the piezoelectric nature of bone. The findings of
Yasuda, et al in 1957 reveal that dried bone crystal exhibits piezoelectric effect one tenth that of
quartz crystal when a strain tension was applied (33). Piezoelectric effect exists when flexion or
torsion is applied to a crystal structure. This torsion causes electrons to move from one end of the
crystal to the other. These concepts were further expanded by Bassett et al. in the 1960s whose
group described that wet bone was also able to produce an electrical potential when mechanical
stress was applied to it (34). This provided a conceptual framework for Wolff’s law. Over the
past 40 years, these foundational ideas have been explored in the context of inducing a growth
response with the application of an electric field or through ultrasonic waves in the form of lowintensity pulsed ultrasound. Biophysical stimulation involves applying direct energy
therapeutics to an injured tissue in order to enhance some cellular function to bring about a
therapeutic, notably, enhanced mineralization and proliferation of osteoblasts (35). Numerous
studies have shown that pulsed electromagnetic fields seem to enhance the proliferation rate of
osteogenic cell lines, and also to induce differentiation to osteogenic cell line, and osteogenic
mineralization (36). Despite promising results in animal and tissue culture models, evidence
16

pointing to a mechanism remains elusive to researchers in this field. In the clinical setting, many
experiments have shown results of decreased healing time, however, there is a lack of
consistency in the measurement parameters for clinical experimentation, such as frequency of
EMF and intensity (37).
Proposed Mechanisms of PEMF stimulation
In a broad view, these studies can be
categorized by their objectives and their
methods. Research has been focused on
three primary areas of experimentation:
induction of cell differentiation,
proliferation, and mineralization all to
form a better understanding of how
PEMF can be used for fracture repair.

Figure 10. This schematic shows the various proposed signal
transduction pathways that can be induced with treatment of
electromagnetic fields or a mechanical strain. All pathways end with
increased activation of calmodulin which leads to increased cell
proliferation (3)

Fibroblast stem cells are used to
determine if that cell line can be induced into the osteoblast fate by
electromagnetic stimulation, if bone cell precursors can be induced
into osteoblasts more efficiently, or if preexisting osteoblasts can be
induced to create more bone matrix than normal to increase healing
as shown in figure 10 (3).
Differentiation
A goal of this research has been to determine if
differentiation of mesenchymal stem cells into osteogenic
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Figure 11. Alkaline phosphatase production and
calcium content both measured and compared to
frequency of PEMF exposure at varying days.
Increased production of both ALP and the
concentration of Calcium can be observed for day
10 and 20 at 40 and 45 Hz. NM=normal growth
medium, OM=osteogenic growth medium (11).

cell fate has can be reliably achieved. Significant work has been done to determine the molecular
events associated with application of PEMF through a pulse generator and the resultant cellular
differentiation that occurs with the application. Recently, Martini et al. found that bone BMP-2
can be upregulated with the application of PEMF at 1.5 mT intensity in human MSCs. It was
further found in this study that p38 (mitogen activated protein kinase, helps with signaling
differentiation and apoptosis) activity was upregulated in the presence of PEMF which is
important for production of osteoblasts (38). Typically, though, alkaline phosphatase or ALPase
is used a marker for differentiation from osteoblast to osteocyte by the deposition of bone matrix
around the developing cells. Similarly, work done by Kang et al also suggests using gene
expression markers such as ALP, and RunX2 as important osteogenic markers for quantifying
the differentiation to osteogenic cell line. The ALP concentration and Calcium concentration
were synergistic when compared with the production of RunX2 (11). A unique aspect of this
study is that they suggest that there appears to be an effective EMF frequency threshold for the
effective stimulation of ALP and Calcium concentration. 7.5 Hz seems to inhibit the osteogenic
proliferation effects in the adipose derived stem cells being studied. This result was occurring
regardless of the growth medium present. They propose in their work that osteogenic
differentiation can be controlled by manipulating the electromagnetic frequency value. This was
a significant finding because the methods employed by this research team showed that under a
unified set of experimental parameters and environmental variables, they were able to modulate
the growth rate of these adipose derived stem cells into osteogenic cell lines. The authors of this
work speculate that there appears to be some underlying mechanism for induction of
osteogenesis that is involved in the resonance frequency for ions such as calcium. This
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movement would be in the form of efflux from the cell. Triggering a strong efflux of calcium ion
from the cell may aid in the production of extracellular matrix and ultimately bone tissue (11).
Proliferation
Many studies discuss the cell proliferation activity that can be measured in fibroblast murine
cells under the stimulation of PEMF. One such study sought to understand the role of the mTOR
pathway in light of the PEMF exposures. The mTOR pathway
has been implicated as an important growth pathway in the
differentiation and proliferation of osteoblasts. Rapamycin was
used in this study as a method of suppression of differentiation
and proliferation (1). When administered in vivo, it can be seen
that rapamycin inhibits the mTOR expression levels despite
PEMF exposure. This indicates that activation of the mTOR
pathway is essential for proliferation and differentiation of
osteoblast cells. Inhibition of the mTOR pathway resulted in

Figure 12. The effects of rapamycin on
the activation of the mTOR pathway.
Activation of the following pathways
are depicted with varying time course
for PEMF exposure. The effects 10
minutes (1).

minimal osteoblast differentiation and proliferation. It was also found that an intensity of 0.4 mT
yielded strong results with mTOR phosphorylation as opposed to the 0.1 mT intensity which was
also evaluated. The effects of the PEMF on the growth pathway seemed to be transient, only
lasting ten minutes. This led the research team to investigate whether intermittent phases of
PEMF was effective as a transient application. The results of this testing showed that the
intermittent PEMF application sustained the prolonged phosphorylation of the mTOR pathway.
BrdU was used to measure the effectiveness of continuous intermittent PEMF exposure. It was
found that BrdU uptake was consistently higher than the continuous PEMF exposure indicating
more cell divisions. ALPase activity in cells was minimal with PEMF exposure in this
19

experiment when compared to the control indicating that PEMF has more effect on osteoblast
proliferation and not the differentiation to osteocyte fate (1). This study can serve as a model for
how clinical studies should be approached. Instead of application windows lasting days and
weeks, emphasis should be placed on an intermittent stimulation window for greater effect if it is
to be used a treatment option for fracture nonunion (1).
One study analyzed varying age demographics for human bone-marrow stem cell samples
from female patients aged 21-30 years of age, and 31-65 years of age. It was found that PEMF
exposure using a commercially available therapeutic device increased the cell count in the 21-30
age demographic. It was shown in this study that PEMF exposure activated extracellular
regulated kinases (ERKs) through phosphorylation with stimulation at just 15 min per day. This
study also measured the ALP levels, type I collagen (COL1A1) through qRT-PCR. These
proteins are osteoblastic and mineralization markers that play an important role in the
development of an osteoblast. They found that Alp and COL1A1 expression were significantly
increased but there was no increase in the osteocalcin (OC) expression with PEMF. A key
finding from this study is that PEMF increased mineralization of the bone-marrow stem cells
during the mineralization but not during differentiation. Of note, this study finds that there
appears to be a factor related to the age of the individual when using hBMSC samples from
female participants. The PEMF exposure was able to induce proliferation of pre-osteoblast cells
up to the age of 30 but the effects on cell cycle regulators and matrix proteins were minimal as
age of donors increased (9). These findings together, suggest that PEMF can stimulate
differentiation, mineralization, and activation of TGF-β signaling in the bone marrow stem cells
of females. It is thought that Eddy currents (loops of electrical current) are generated around the
cell initially which can enhance the phosphorylation reaction of ERK which enhances BMSC
20

proliferation. After the BMSCs reach confluence (all
surface area of plate has been covered by a monolayer
of cells) and the growth medium is changed to that of
differentiation, it is proposed that these Eddy currents
cause decrease in fibrillin 2, which then increases TGFβ2 availability. As depicted by the researchers in figure
13 (9).
The possible activity of electromagnetic fields
causing Eddy currents is disputed. Evidence put forth by
Kavand et al suggests that a more probable mechanism
of activation of these pathways lies in tuning the PEMF
parameters such that they match the ion cyclotron
resonance frequencies of calcium ion (39). This is an
important step in understanding how exactly
electromagnetic fields may interact with a biological
system. Because the extracellular fluid surrounding cells
has little medium with which to carry electrons in an
induced current, the mechanism must be through the

Figure 13. Proposed mechanism of action by
Selvamurugan et al showing that (B) magnetic
field acts on the hBMSC to induce eddy currents
which surround it and increase the effects of ERK
which leads to increased proliferation of hBMSC.
TGF-β2, miR21-5p, are upregulated, while fibrillin
2 is down regulated. All of which leads to the
autocrine signaling of TGF-β2 and increased
activity of SMAD2/4 with an end result of
increased alkaline phosphatase activity and
COL1(9)

action on specific solute ions in that fluid. This current is then carried by sodium, potassium, and
calcium ions. Greater research emphasis should be placed on elucidating the effects of PEMF
which matches the cyclotron resonance frequency of the principal ion, being calcium, on the cell
membranes (39).
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Growth Factor Synthesis
As reported by Chang et al. PEMF effect on bone formation could depend on the
developmental phase of the cell line used which introduces a complicating variable in
experimentation and one that must be considered (40). The current in vitro studies have shown
that biophysical stimulation causes stem cells to differentiate into an osteoblast, secrete matrix
glycoproteins such as osteopontin and osteocalcin. It should be noted that the biophysical
manipulation techniques used in vitro are comparable to the results obtained from TGF-β1,
BMPs, and IGF-1. Additionally, increased mineralization process, and reduction in the formation
of osteoclast cells which resorb bone matrix. Wang et al. found that in osteoblastic murine cell
line, MC3T3-E1, the growth factors, BMP-2 through 7 were considerably upregulated compared
to normal agonist mRNA expression. Additionally, alkaline phosphatase activity was increased
above normal levels within the cells. This indicates that controlled exposure of osteoblastic cell
lines to PEMF can induce osteoinductive growth factors eventually leading to terminal
differentiation of those cells (41).
Clinical Evidence for PEMF
The use of PEMF extends beyond both animal models and tissue culture experiments, it
has been attempted in the clinical setting in the treatment of fracture nonunions with highly
mixed results. The underlying reason for this is that the clinical experiments need to be
tailored to an understanding of the underlying mechanisms of action. Due to this fact, there is
no widely agreed upon standard set of experimental parameters (42, 43). Many studies have
had favorable results to date, however, due to the broad diversity in the experimental design,
i.e., low sample sizes, non-randomized, there has been no conclusive evidence (42). Indeed,
there is even variation in the signal intensity, waveform, and frequency of the applied PEMF
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on both animal models and human patients. All of these factors contribute to the lack of
consensus in the clinical evidence (44).
Discussion
The treatment of fracture nonunions remains a great challenge in orthopedic medicine.
Autologous bone graft remains the gold standard for the treatment of atrophic nonunions
however the risks associated with the procedure warrant new avenues of research that explore the
use of bone marrow aspirates, MSC injection, and demineralized bone matrix to enhance the
fracture healing process. The use of biophysical manipulation and electromagnetic fields to
induce fracture healing still require further evidence and narrowing of the experimental
parameters in tissue culture experiments. Clinically, the use of biophysical manipulation as a
noninvasive means to enhance fracture healing still remain in level III evidence, more
randomized controlled trials and elucidation of a unified mechanism need to be done.
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